Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
46
CVAC Quote, Financials, Valuation and Earnings
Last price:
$4.47
Seasonality move
:
-23.63%
Day range:
$4.43 - $4.73
52-week range:
$2.37 - $5.28
Dividend yield:
0%
P/E ratio:
4.95x
P/S ratio:
1.75x
P/B ratio:
1.44x
Volume:
854.1K
Avg. volume:
680.7K
1-year change:
18.57%
Market cap:
$1B
Revenue:
$579.3M
EPS (TTM):
$0.90
Analysts' Opinion
-
Consensus RatingCureVac NV has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.29, CureVac NV has an estimated upside of 40.75% from its current price of $4.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.02 representing 100% downside risk from its current price of $4.47.
Fair Value
-
According to the consensus of 4 analysts, CureVac NV has 40.75% upside to fair value with a price target of $6.29 per share.
CVAC vs. S&P 500
-
Over the past 5 trading days, CureVac NV has overperformed the S&P 500 by 5.47% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CureVac NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CureVac NV revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter CureVac NV reported revenues of $939.6K.
Earnings Growth
-
CureVac NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CureVac NV reported earnings per share of -$0.24.
Enterprise value:
528M
EV / Invested capital:
--
Price / LTM sales:
1.75x
EV / EBIT:
2.24x
EV / Revenue:
0.92x
PEG ratio (5yr expected):
--
EV / Free cash flow:
3.37x
Price / Operating cash flow:
6.42x
Enterprise value / EBITDA:
2.07x
Gross Profit (TTM):
$504.6M
Return On Assets:
25.91%
Net Income Margin (TTM):
35.46%
Return On Equity:
32.68%
Return On Invested Capital:
32.68%
Operating Margin:
-6128.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $52.4M | $64M | $575.1M | $13.4M | $939.6K | |
| Gross Profit | -$121.3M | -$93.7M | $504.6M | -$31.8M | $18.9K | |
| Operating Income | -$306.1M | -$311.2M | $222.6M | -$79.6M | -$57.6M | |
| EBITDA | -$278.2M | -$269M | $255.3M | -$70.3M | -$49.2M | |
| Diluted EPS | -$1.57 | -$1.32 | $0.90 | -$0.34 | -$0.24 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $880.9M | $749M | $408.1M | $507.7M | |
| Total Assets | -- | $1.1B | $1.1B | $745.6M | $803.4M | |
| Current Liabilities | -- | $265.5M | $98.5M | $181.3M | $66.3M | |
| Total Liabilities | -- | $392.6M | $283.8M | $263M | $103.4M | |
| Total Equity | -- | $753.2M | $777.9M | $482.6M | $699.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$255.6M | -$287.9M | $171.6M | -$104.9M | -$43.5M | |
| Cash From Investing | -$93.5M | -$51.2M | -$15M | -$5.5M | -$537.7K | |
| Cash From Financing | $319.2M | -$3.3M | -$5.7M | -$1.2M | -$1.4M | |
| Free Cash Flow | -$348.7M | -$339.1M | $156.6M | -$110.4M | -$44.1M | |
CVAC
Sector
Market Cap
$1B
$33.4M
Price % of 52-Week High
84.66%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
0.26%
-0.66%
1-Year Price Total Return
18.57%
-40%
Beta (5-Year)
--
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.29
200-day SMA
Buy
Level
$3.23
Bollinger Bands (100)
Buy
Level
2.99 - 3.95
Chaikin Money Flow
Sell
Level
-2.4M
20-day SMA
Buy
Level
$3.83
Relative Strength Index (RSI14)
Buy
Level
65.61
ADX Line
Buy
Level
42.95
Williams %R
Neutral
Level
-22.4913
50-day SMA
Buy
Level
$3.36
MACD (12, 26)
Buy
Level
0.38
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.893)
Buy
CA Score
(Annual)
Level (2.0841)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-7.8813)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Stock Forecast FAQ
In the current month, CVAC has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CVAC average analyst price target in the past 3 months is $6.29.
-
Where Will CureVac NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that CureVac NV share price will rise to $6.29 per share over the next 12 months.
-
What Do Analysts Say About CureVac NV?
Analysts are divided on their view about CureVac NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CureVac NV is a Sell and believe this share price will drop from its current level to $2.02.
-
What Is CureVac NV's Price Target?
The price target for CureVac NV over the next 1-year time period is forecast to be $6.29 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CVAC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CureVac NV is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CVAC?
You can purchase shares of CureVac NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CureVac NV shares.
-
What Is The CureVac NV Share Price Today?
CureVac NV was last trading at $4.47 per share. This represents the most recent stock quote for CureVac NV. Yesterday, CureVac NV closed at $4.47 per share.
-
How To Buy CureVac NV Stock Online?
In order to purchase CureVac NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
